A Double-blind, Multiple-dose, 52-week Study to Evaluate the Efficacy and Safety of Testosterone Enanthate Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Testosterone enanthate (Primary)
- Indications Hypogonadism
- Focus Registrational; Therapeutic Use
- Acronyms STEADY
- Sponsors Antares Pharma
- 08 Aug 2017 According to an Antares Pharma media release, data from this trial has been presented at a moderated poster session at the annual American Urological Association meeting 2017.
- 16 May 2017 According to an Antares Pharma media release, data from the study will be presented at the American Urological Association Annual Meeting 2017.
- 16 May 2017 Results published in an Antares Pharma media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History